Article Per Year (5 Year)
p-Index From 2021 - 2026
3.856
P-Index
This Author published in this journals
All Journal Jurnal Kesehatan Andalas INDONESIAN JOURNAL OF PHARMACY Universa Medicina Media Ilmu Kesehatan Oto Rhino Laryngologica Indonesiana Majalah Kedokteran Andalas Bioscientia Medicina : Journal of Biomedicine and Translational Research Poltekita : Jurnal Ilmu Kesehatan Health and Medical Journal Jurnal Dunia Gizi Bioscientia Medicina : Journal of Biomedicine and Translational Research Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI) Scientific Journal Jurnal Ilmu Kesehatan Indonesia (JIKSI) The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy Jurnal Penyakit Dalam Indonesia Jurnal Pengabdian Masyarakat Kesehatan (JURABDIKES) Jurnal Riset Ilmiah Neurona Indonesian Journal of Endocrinology Metabolism and Diabetes (InaJEMD)
Eva Decroli
Endocrinology And Metabolic Subdivision, Division Of Internal Medicine, Dr. M. Djamil General Hospital/ Medical Faculty Of Andalas University, Padang, West Sumatera, Indonesia
Humanities Biochemistry, Genetics & Molecular Biology Economics, Econometrics & Finance Health Professions Immunology & microbiology Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology Neuroscience Nursing Public Health Social Sciences Other

Published : 47 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search
Journal : Scientific Journal

 1 
Marine-Lenhart Syndrome: Current Perspectives on Diagnosis and Management Alexander Kam; Yanne Pradwi Efendi; Dinda Aprilia; Eva Decroli; Syafril Syahbuddin; Suci Berlian Hemilton
Scientific Journal Vol. 4 No. 5 (2025): SCIENA Volume IV No 5, September 2025
Publisher : CV. AKBAR PUTRA MANDIRI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56260/sciena.v4i5.264

Abstract

Marine-Lenhart syndrome (MLS) is an uncommon disorder characterised by the concurrent presence of Graves’ disease and hyperfunctioning thyroid nodules. Its global prevalence ranges between 2.7- 4.1% of Graves’ disease cases, presenting significant challenges in diagnosis and management. MLS is often difficult to detect due to limitations in autoimmune serology tests, thyroid ultrasonography, and access to nuclear medicine facilities. Diagnosis relies on a combination of clinical hyperthyroidism symptoms, the presence of specific thyroid antibodies, and scintigraphy findings that reveal "hot" or "cold" nodules. The primary therapeutic options for MLS include antithyroid drugs, radioactive iodine (RAI) therapy, and surgery. RAI is commonly employed as definitive treatment, often requiring higher doses to address the resistance of hyperfunctioning nodules. Surgery is indicated in cases involving large nodules, compressive symptoms, or suspected malignancies. Treatment strategies should be tailored to the individual clinical characteristics of each patient to minimize complications and ensure optimal outcomes. Advancing the diagnosis and management of MLS requires enhanced access to advanced diagnostic technologies and improved healthcare provider proficiency in identifying and treating the syndrome. A multidisciplinary and integrated approach is essential for achieving favorable clinical outcomes for MLS patients.
Liothyronine Therapy in Hypothyroidism Dinda Aprilia; Eva Decroli; Alexander Kam; Jonggara Oktaviandra Siahaan
Scientific Journal Vol. 4 No. 5 (2025): SCIENA Volume IV No 5, September 2025
Publisher : CV. AKBAR PUTRA MANDIRI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56260/sciena.v4i5.277

Abstract

Hypothyroidism is a clinical condition characterized by reduced production of thyroid hormones and is among the most common endocrine disorders, affecting about 3% of the general population, with a higher prevalence in women (5.1%) than in men (0.9%). In Indonesia, the prevalence of hypothyroidism is estimated at 5-10%. Despite achieving normal thyroid stimulating hormone (TSH) levels with levothyroxine (LT4) therapy, many patients continue to experience symptoms like fatigue, depression, and cognitive impairment, which impact their quality of life. A study of 969 hypothyroid patients found that 77.6% were dissatisfied with their treatment and reported low quality of life scores. Although LT4 has been the standard therapy for nearly 50 years due to its stability and the peripheral conversion of thyroxine (T4) to triiodothyronine (T3), recent recommendations from experts in developed countries suggest using liothyronine (LT3) monotherapy or a combination of LT3 and LT4 in selected cases.
Emerging Biomarkers for Prediabetes : A Review Dinda Aprilia; Eva Decroli; Alexander Kam; Putri Deas Hadilofyani
Scientific Journal Vol. 4 No. 6 (2025): SCIENA Volume IV No 6, November 2025
Publisher : CV. AKBAR PUTRA MANDIRI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56260/sciena.v4i6.278

Abstract

Prediabetes is a global health concern marked by elevated blood glucose levels that do not yet meet the threshold for type 2 diabetes mellitus (T2DM). It is often underdiagnosed despite being associated with insulin resistance, beta-cell dysfunction, and increased cardiovascular risk. Improved strategies for early detection are crucial to prevent disease progression. This review aims to explore novel biomarkers associated with prediabetes and evaluate their potential clinical applications in early diagnosis and risk stratification. A literature search was conducted on English and Indonesian language publications, including original research, case reports, and expert guidelines, focusing on emerging molecular and metabolic biomarkers related to prediabetes. Several promising biomarkers have been identified, including adiponectin, microRNAs, fetuin A, alpha-hydroxybutyrate (α-HB), and Protein Z. Adiponectin demonstrates an inverse relationship with insulin resistance. Specific microRNAs, such as miR-192 and miR-193b, are implicated in glucose metabolism and beta-cell function. Elevated fetuin A levels are linked to hepatic insulin resistance, while increased α-HB levels reflect early metabolic shifts in glucose utilization. Additionally, altered Protein Z concentrations may contribute to prothrombotic states in individuals with prediabetes. In conclusion, these biomarkers offer valuable insight into the pathophysiology of prediabetes and hold potential for enhancing early detection and prevention strategies. However, further validation through large-scale studies is needed before their integration into clinical practice
The Role of Genomic Sequencing in Diabetes Mellitus Yanne Pradwi Efendi; Alexander Kam; Eva Decroli; Dinda Aprilia; Syafril Syahbuddin
Scientific Journal Vol. 4 No. 5 (2025): SCIENA Volume IV No 5, September 2025
Publisher : CV. AKBAR PUTRA MANDIRI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56260/sciena.v4i5.279

Abstract

Diabetes Mellitus is a chronic metabolic disorder caused by impaired insulin secretion and/or insulin resistance. Genetic testing through genomic sequencing is one of the modalities available for diabetes mellitus. Genomic sequencing is the process of analysing DNA obtained from a blood sample (or alternatively from tissue samples). Broadly, genomic sequencing plays two major roles in diabetes mellitus: supporting diagnosis and guiding therapeutic approaches. In its development, genomic sequencing has proven valuable for diagnostic investigation in type 1 diabetes and maturity-onset diabetes of the young (MODY), as well as for assessing the polygenic risk score (PRS) in type 2 diabetes. Establishing a definitive diagnosis allows for the selection of individualised therapy. Several randomised controlled trials have demonstrated that the risk of developing diabetes can be reduced by up to half if detected at an earlier stage. Moreover, genomic sequencing can identify genetic variants that influence responsiveness to antidiabetic treatments. At present, several potential antidiabetic agents targeting novel pathways are under development and in various stages of clinical trials. The application of genomic sequencing thus facilitates the implementation of individualised therapy, ultimately contributing to the realisation of precision medicine.
Co-Authors Adang Bachtiar Ade Chandra Afriwardi Afriwardi Ahmad, Armen Al Hafiz Alexander Kam Alexander Kam Alexander Kam Alexander Kam Alfitri, Maura Salsabila Andi Fadilah Yusran Putri Antoni, Adi Aprilia, Dinda Asman Manaf Aulia, Salsabila Syafna Auliangi Tamayo Brian Sri Prahastuti Darwin Amir, Darwin Deddy Saputra Delmi Sulastri Dessy Arisanty Dinda Aprilia Dinda Aprilia Dinda Aprilia Dinda Aprilia Dwitya Elvira, Dwitya Efendi, Nursyirwan Efendi, Yanne Pradwi Ellyza Nasrul Eryati Darwin Eti Yerizel Fadella, Annesa Fadrian, Fadrian Fahrurozi, R. Ifan A. Fauzar Fauzar Fereshti Lailani Finisia Noviyanti Firdawati Firdawati Garri Prima Decroli Genta Pradana, Genta Hafni Bachtiar Hardisman Harie Satria ES Husna Yetti Jannah, Lidya Raudhatul Jonggara Oktaviandra Siahaan Kam, Alexander Linosefa Linosefa Martini, Rose D Meliza Wahyuni Mudjiran Muhammad Luthfi Muharramah, Disa Hijratul Murni, Arina W Mustafa Noer Muthia Faurin Nada Utami Prahastiwi Nadila Andam Astari Namanda Putri, Athari Fadhila Nining Kurniawati Nur Indrawati Lipoeto Nurhayati Nurhayati Prayitno, Irwan Putri Deas Hadilofyani Putri Sri Lasmini Putri, Biomechy Oktomalio Putri, Septia Harma Putri, Vidola Yasena Rahayuningsih, Sri Puji Restu Susanti Risviani, Darayani Ritonga, Sukhri Herianto Robby Satria Putra Roza Kurniati Roza Mulyana Saptino Miro Saptino Miro, Saptino Sheila Jihan Safira Sofiani, Dinda Putri Suci Berlian Hemilton Sukri Rahman Susila Sastri Syafril Syahbuddin Syafril Syahbuddin Syafril Syahbuddin Tamayo, Auliangi Try Rahmi Lussii Karsuita Ulvyana, Vyora Viotra, Deka Yanne Pradwi Efendi Yanne Pradwi Efendi Yoga, Vesri Yulia, Dwi Yuliarni Syafrita Yusrawati Yusrawati Yustini Alioes Zelly Dia Rofinda